SCHEMBL2912296

SCHEMBL2912296

CC(C)Oc1cc([N+](=O)[O-])ccc1N1CCN(C)CC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.52
LMNA P02545 5/20 0.52
KMT2A Q03164 2/20 0.52
GAA P10253 2/20 0.52
POLB P06746 1/20 0.52
SIRT6 Q8N6T7 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
MAPT P10636 1/20 0.51
MAPK1 P28482 1/20 0.51
KDM4E B2RXH2 1/20 0.51
HTT P42858 2/20 0.50
CYP1A2 P05177 2/20 0.50
CYP3A4 P08684 2/20 0.50
CYP2C19 P33261 2/20 0.50
MEN1 O00255 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
WDR5 P61964 3/20 0.49
CYP19A1 P11511 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL3878149 0.99 ALDH1A1 (0.51) ALDH1A1LMNAKMT2AGAAPOLB
SCHEMBL28526104 0.87 ALDH1A1 (0.48) ALDH1A1LMNAKMT2AGAAPOLB
SCHEMBL28523902 0.86 ALDH1A1 (0.60) ALDH1A1LMNAKMT2AGAAPOLB
SCHEMBL20242265 0.86 ALDH1A1 (0.57) ALDH1A1LMNAKMT2APOLBSMN1; SMN2
SCHEMBL29556577 0.85 ALDH1A1 (0.64) ALDH1A1LMNAKMT2AGAASIRT6
SCHEMBL2062270 0.85 ALDH1A1 (0.64) ALDH1A1LMNAKMT2AGAASIRT6
SCHEMBL28528987 0.82 DRD2 (0.49) ALDH1A1LMNAGAAPOLBSMN1; SMN2
SCHEMBL28520443 0.82 CYP19A1 (0.48) ALDH1A1LMNAGAAPOLBSMN1; SMN2
SCHEMBL26644457 0.81 ALDH1A1 (0.51) ALDH1A1LMNAKMT2AGAAPOLB
SCHEMBL28507271 0.81 ALDH1A1 (0.59) ALDH1A1LMNAGAASIRT6SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2010496-B1 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS ASTRAZENECA AB (SE) 2010-08-25 EP disclosed
CN-101466682-A 4-anilinoquinolina-3-carboxamidas como inhibidores de la quinasa CSF-1R ASTRAZENECA AB (SE) 2009-06-24 CN disclosed
US-20090054411-A1 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS ASTRAZENECA AB (SE) 2009-02-26 US disclosed
EP-2010496-A1 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS AstraZeneca AB (SE) 2009-01-07 EP disclosed
WO-2007119046-A1 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS ASTRAZENECA AB (SE) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054411-A1 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS CSF1R, CSF3R, FLT3 ALDH1A1 1650/4885LMNA 3715/4885KMT2A 273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.